An experimental weight loss pill cut body weight by up to 12% in 36 weeks

An experimental weight-loss pill called aleniglipron helped adults with obesity lose up to 12.1% of their body weight over 36 weeks in a placebo-controlled phase 2b trial, according to results published Monday in Nature Medicine. The 12.1% figure is in the same range as what injectable peptide GLP-1 drugs Ozempic and Wegovy have produced, though the ACCESS trial was not designed to compare against them directly. Aleniglipron is a non-peptide, chemically synthesized small molecule designed for once-daily oral dosing, with or without food, according to Structure Therapeutics, and that chemistry sidesteps the cold-chain storage, peptide synthesis, and injector-device manufacturing that currently cap access to the injectable class.

GLP-1 drugs mimic a gut hormone that affects insulin, appetite, and fullness. The current blockbusters, Novo Nordisk's semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and Eli Lilly's tirzepatide (Mounjaro and Zepbound), are peptide drugs. Peptides are short chains of amino acids, the building blocks of proteins, and they have to be injected because the stomach would digest them. To make them at scale, manufacturers have to build peptide synthesis capacity, keep the drugs refrigerated, and ship them with injector pens. Each of those steps has been a bottleneck as global demand has outrun supply.

A small molecule is a different beast. It is built through ordinary organic chemistry, the way most pills on a pharmacy shelf are built. That means it can be compressed into a tablet, stored at room temperature, and produced in the same kind of factories that already make generic drugs. It is the difference between a biologic drug that needs a refrigerator and a pill you can keep in your medicine cabinet.

The ACCESS trial enrolled 230 adults, average age around 50, with obesity or overweight, across 38 U.S. medical centers, with Kushner. The 12.1% is a placebo-adjusted readout, meaning the placebo arm also lost some weight and the headline number reflects the drug's effect above that. The trial ran for 36 weeks, long enough to see a clear signal but not long enough to show durability beyond a year.

The drug class is no longer a one-program field. Pfizer has danuglipron in late-stage trials, Eli Lilly has orforglipron moving through phase 3, and Novo Nordisk has amycretin, a dual GLP-1/amylin agonist, in earlier development. Pfizer had a setback in late 2023 with a different oral GLP-1 formulation over liver-safety concerns, then returned with a once-daily version. Each program is betting that an oral, easy-to-manufacture GLP-1 can capture a slice of the demand the injectables have not been able to serve, according to a tracker of next-generation GLP-1 developers.

The catch is that the 12.1% is a phase 2b readout, not approval. Structure Therapeutics, the sponsor, has not yet announced a phase 3 timeline, and the Nature Medicine paper has not been independently audited in a head-to-head comparison against semaglutide. GI tolerability, the main reason patients stop the injectable GLP-1s, will need to read out cleanly in larger and longer trials. The company is one of several small-molecule GLP-1 developers, and the field's history of late-stage failures, including Pfizer's 2023 liver-safety pause and earlier orforglipron setbacks, is a reminder that a strong phase 2 result does not guarantee a phase 3 win.

If the data hold, the implication is that the GLP-1 class is shifting from peptide to small-molecule chemistry, with manufacturing and access consequences that ride on the synthesis path, not on the route of administration. Whichever small-molecule GLP-1 reaches approval first will not be defined by its weight-loss percentage but by whether it can be produced at the volumes the current injectable supply chain cannot reach.